Pharvaris (NASDAQ:PHVS) Stock Rating Lowered by Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

PHVS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada began coverage on Pharvaris in a research note on Monday, March 9th. They issued an “outperform” rating and a $52.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.70.

Pharvaris Price Performance

Pharvaris stock opened at $28.56 on Friday. The company’s fifty day simple moving average is $27.05 and its 200-day simple moving average is $25.43. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.85. The stock has a market cap of $1.55 billion, a P/E ratio of -8.47 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Monday, April 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.14). On average, equities research analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc lifted its holdings in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi lifted its holdings in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, HighVista Strategies LLC boosted its position in shares of Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after buying an additional 971 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.